One measurement core,
eleven medical applications.
NL-SWI is a patent-pending measurement method, not a single device. The same measurement core is the intended starting point for the eleven medical applications below — ranked by medical importance, not by how close each one is to market.
This is today's roadmap, not a ceiling on where the platform can go. None of these applications has clinical validation or regulatory clearance yet — each is a direction we're building toward.
Where earlier detection changes outcomes.
Applications where earlier or better detection has the most direct effect on survival and long-term outcome.
Bedside stroke detection
Designed to detect and monitor stroke at the bedside without a CT scan — a frequency low enough to cross the skull while keeping its precision.
Atherosclerotic plaque characterization
Designed to distinguish soft from calcified plaque by its acoustic signature — aimed at flagging higher-risk plaque earlier. A contributing signal, not a stand-alone predictive claim.
Tumor characterization
A virtual-biopsy direction: characterizing suspicious tissue non-invasively, aimed at reducing biopsies performed on tissue that turns out to be benign.
Universal diagnostic imager
General-purpose imaging positioned to complement — and in some settings reduce dependence on — MRI, CT and PET-CT: no radiation, no contrast agent, portable.
Supporting diagnosis and treatment.
Applications that support diagnosis or treatment of conditions with major clinical consequence — generally less acutely time-critical than Group 1.
Virtual catheterization
3D arterial imaging — coronary, cerebral, peripheral — designed to make catheter insertion unnecessary: no contrast agents, no radiation, outpatient setting.
Intra-body navigation
Guidance for interventional procedures, targeting sub-millimeter precision without the radiation exposure of fluoroscopy.
Vascular access guidance
Bedside guidance for central-line placement, aimed at first-attempt success without X-ray confirmation.
Liver fibrosis / NASH monitor
Designed to track liver fibrosis progression non-invasively — for the setting where biopsy is invasive and existing elastography tools are limited.
Daily convenience, long-term tracking.
High-frequency, lower-acuity use — where the value is in daily convenience and long-term tracking rather than a single critical reading.
Non-invasive glucose monitor
Glucose trend readings through closed eyelids — designed to return a trend in seconds, with no lancet or test strip. The method is designed to track the speed of sound in the eye's fluid, which shifts with dissolved sugar.
Age Back Pro
A clinical-grade device for longevity and executive-health clinics, aimed at objectively tracking cognitive and biological aging markers over time, visit to visit.
Age Back Home
A window beneath the skin's surface — collagen density, elasticity, biological skin age — designed to track rejuvenation treatments objectively over time.
Said plainly, so it never needs walking back.
Every intended use above is bounded on purpose. Regulatory pathways — 510(k), De Novo, PMA — depend on final claims and have not been determined.
What to ask before you ask us.
Is there a built device today?
The absolute brief — No. NL-SWI is a patent-pending measurement method, not a product. Every application on this page is a design goal - the first device is the next milestone, and nothing here is a measured clinical result.
Why are these applications ranked this way?
The absolute brief — By medical importance, not by distance to market. The same measurement core radiates outward — from acute, life-critical uses like bedside stroke detection to high-frequency daily uses like glucose trends and skin-age tracking.
Does the platform use radiation or contrast agents?
The absolute brief — No. The method is acoustic by design — intended to work without ionizing radiation and without contrast agents, which is precisely what makes repeat, longitudinal tracking practical.
Which application will you build first?
The absolute brief — That is the conversation we are having with partners. The roadmap is bounded but open: the first vertical we build toward will be selected together with a development partner, based on clinical need and regulatory pathway.
Which vertical should we prove first?
We are selecting a partner, not asking for one.
Choose with us